Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR15314-33] to ALIX - N-terminal
- Suitable for: WB
- Knockout validated
- Reacts with: Human
Product nameAnti-ALIX antibody [EPR15314-33] - N-terminal
See all ALIX primary antibodies
DescriptionRabbit monoclonal [EPR15314-33] to ALIX - N-terminal
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Human
Recombinant fragment within Human ALIX aa 1-150. The exact sequence is proprietary.
Database link: Q8WUM4
- WB: HeLa, Jurkat, K562 and 293 cell lysates
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab186728 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Detects a band of approximately 97, 80 kDa (predicted molecular weight: 97 kDa).|
FunctionClass E VPS protein involved in concentration and sorting of cargo proteins of the multivesicular body (MVB) for incorporation into intralumenal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome. Binds to the phospholipid lysobisphosphatidic acid (LBPA) which is abundant in MVBs internal membranes. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis and enveloped virus budding (HIV-1 and other lentiviruses). Appears to be an adapter for a subset of ESCRT-III proteins, such as CHMP4, to function at distinct membranes. Required for completion of cytokinesis. Involved in HIV-1 virus budding. Can replace TSG101 it its role of supporting HIV-1 release; this function implies the interaction with CHMP4B. May play a role in the regulation of both apoptosis and cell proliferation.
Sequence similaritiesContains 1 BRO1 domain.
Cellular localizationCytoplasm > cytosol. Melanosome. Cytoplasm > cytoskeleton > centrosome. Identified by mass spectrometry in melanosome fractions from stage I to stage IV. Colocalized with CEP55 in the midbody during cytokinesis. Colocalized with CEP55 at centrosomes of non-dividing cells.
- Information by UniProt
- AIP1 antibody
- ALG 2 interacting protein 1 antibody
- ALG-2-interacting protein 1 antibody
All lanes : Anti-ALIX antibody [EPR15314-33] - N-terminal (ab186728) at 1/5000 dilution
Lane 1 : Wild-type HEK-293 whole cell lysate
Lane 2 : ALIX knockout HEK-293 whole cell lysate
Lane 3 : HeLa whole cell lysate
Lysates/proteins at 20 µg per lane.
Predicted band size: 97 kDa
Observed band size: 96 kDa why is the actual band size different from the predicted?
Lanes 1 - 3: Merged signal (red and green). Green - ab186728 observed at 96 kDa. Red - loading control, ab8245, observed at 37 kDa.
ab186728 was shown to recognize in wild-type HEK-293 cells as signal was lost at the expected MW in ALIX knockout cells. Additional cross-reactive bands were observed in the wild-type and knockout cells. Wild-type and ALIX knockout samples were subjected to SDS-PAGE. The membrane was blocked with 3% Milk. ab186728 and ab8245 (Mouse anti GAPDH loading control) were incubated overnight at 4°C at 1/5000 dilution and 1/20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed ab216776 secondary antibodies at 1/20000 dilution for 1 hour at room temperature before imaging.
All lanes : Anti-ALIX antibody [EPR15314-33] - N-terminal (ab186728) at 1/10000 dilution
Lane 1 : 293 cell lysate
Lane 2 : K562 cell lysate
Lane 3 : Jurkat cell lysate
Lane 4 : HeLa cell lysate
Lysates/proteins at 20 µg per lane.
All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution
Predicted band size: 97 kDa
ab186728 has been referenced in 2 publications.
- Mussack V et al. Comparing small urinary extracellular vesicle purification methods with a view to RNA sequencing-Enabling robust and non-invasive biomarker research. Biomol Detect Quantif 17:100089 (2019). PubMed: 31194192
- Hermann S et al. Transcriptomic profiling of cell-free and vesicular microRNAs from matched arterial and venous sera. J Extracell Vesicles 8:1670935 (2019). PubMed: 31632620